Integrated Investment Consultants LLC bought a new position in shares of ResMed Inc. (NYSE:RMD - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 6,025 shares of the medical equipment provider's stock, valued at approximately $1,378,000.
A number of other large investors have also bought and sold shares of the stock. UMB Bank n.a. increased its holdings in ResMed by 1.9% during the 3rd quarter. UMB Bank n.a. now owns 2,465 shares of the medical equipment provider's stock worth $602,000 after purchasing an additional 47 shares in the last quarter. Ascent Group LLC increased its stake in ResMed by 1.7% in the 3rd quarter. Ascent Group LLC now owns 2,924 shares of the medical equipment provider's stock valued at $714,000 after buying an additional 48 shares during the last quarter. SkyView Investment Advisors LLC lifted its position in shares of ResMed by 2.0% during the 3rd quarter. SkyView Investment Advisors LLC now owns 2,610 shares of the medical equipment provider's stock worth $637,000 after buying an additional 51 shares in the last quarter. Wedmont Private Capital boosted its stake in shares of ResMed by 2.6% in the 4th quarter. Wedmont Private Capital now owns 2,032 shares of the medical equipment provider's stock worth $475,000 after buying an additional 52 shares during the last quarter. Finally, Concurrent Investment Advisors LLC grew its holdings in shares of ResMed by 3.1% in the third quarter. Concurrent Investment Advisors LLC now owns 1,919 shares of the medical equipment provider's stock valued at $469,000 after acquiring an additional 57 shares in the last quarter. 54.98% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at ResMed
In other news, Director Witte Jan De sold 796 shares of the stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $248.81, for a total value of $198,052.76. Following the transaction, the director now owns 6,723 shares of the company's stock, valued at $1,672,749.63. This represents a 10.59 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Peter C. Farrell sold 2,000 shares of the firm's stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $245.65, for a total transaction of $491,300.00. Following the sale, the director now owns 81,218 shares in the company, valued at approximately $19,951,201.70. This trade represents a 2.40 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,099 shares of company stock valued at $2,719,385. 0.71% of the stock is currently owned by company insiders.
ResMed Price Performance
RMD traded up $2.76 during trading on Friday, reaching $239.89. 776,857 shares of the company were exchanged, compared to its average volume of 670,396. ResMed Inc. has a 12-month low of $170.39 and a 12-month high of $260.49. The company's 50-day moving average is $238.51 and its two-hundred day moving average is $232.77. The company has a quick ratio of 1.91, a current ratio of 2.92 and a debt-to-equity ratio of 0.13. The company has a market cap of $35.22 billion, a price-to-earnings ratio of 31.77, a P/E/G ratio of 1.69 and a beta of 0.70.
ResMed (NYSE:RMD - Get Free Report) last announced its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.03 by $0.17. The firm had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.19 billion. ResMed had a net margin of 23.15% and a return on equity of 25.53%. The company's revenue for the quarter was up 11.1% on a year-over-year basis. During the same period in the prior year, the firm posted $1.64 earnings per share. Research analysts forecast that ResMed Inc. will post 9.36 earnings per share for the current fiscal year.
ResMed Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Thursday, December 12th. Stockholders of record on Thursday, November 7th were given a dividend of $0.53 per share. The ex-dividend date of this dividend was Thursday, November 7th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.88%. ResMed's dividend payout ratio (DPR) is currently 28.08%.
Wall Street Analysts Forecast Growth
A number of analysts recently commented on the company. Piper Sandler started coverage on ResMed in a report on Friday, January 10th. They set a "neutral" rating and a $252.00 price target on the stock. StockNews.com raised shares of ResMed from a "hold" rating to a "buy" rating in a report on Tuesday, October 15th. KeyCorp raised their price objective on shares of ResMed from $251.00 to $266.00 and gave the stock an "overweight" rating in a report on Friday, October 25th. Stifel Nicolaus started coverage on shares of ResMed in a research note on Friday, December 13th. They issued a "hold" rating and a $250.00 target price on the stock. Finally, Royal Bank of Canada raised their price target on shares of ResMed from $224.00 to $232.00 and gave the stock a "sector perform" rating in a research note on Friday, October 25th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, ResMed presently has an average rating of "Hold" and an average target price of $233.09.
Read Our Latest Stock Report on ResMed
ResMed Profile
(
Free Report)
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.
Featured Stories
Before you consider ResMed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ResMed wasn't on the list.
While ResMed currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
